amcure gmbh logo

Amcure GmbH

amcure leverages its exceptional knowledge of CD44 target biology to develop a pipeline of innovative therapeutic programs. In cancer, blocking the extracellular target CD44v6 could have a beneficial impact on several relevant receptor tyrosine kinase pathways. Using this unique approach, our lead compound, AMC303, has entered clinical development in solid tumors in Q4 2016.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://amcure.com
Founded2011
Disease Focus
Development StageClinical
STOCK CODENon Listed
Address
Herrmann-von-Helmholtz-Platz 1, 76344
Eggenstein-Leopodshafen
Germany
Email
Contact Number
+49 721 608 221 47

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/amcure-gmbh” connections=”true” suffix=””]